Arcturus Therapeutics: Innovating mRNA Vaccines and Treatments for Global Health Challenges

Arcturus Therapeutics: Pioneering the Future of mRNA Medicine

Arcturus Therapeutics Holdings Inc., based in San Diego and founded in 2013, is at the forefront of developing messenger RNA (mRNA) therapies and vaccines targeting infectious diseases and rare conditions affecting the liver and respiratory systems. The company leverages its proprietary technologies such as LUNAR® lipid-mediated delivery and STARR® mRNA Technology to create a diverse and promising pipeline of RNA therapeutic candidates. Among its notable achievements is the development of KOSTAIVE®, recognized as the world’s first self-amplifying mRNA COVID vaccine, which has already received approval. This groundbreaking product highlights Arcturus's commitment to innovation in the rapidly evolving field of mRNA medicines.

In addition to its pioneering vaccine efforts, Arcturus has formed a strategic global collaboration with CSL Seqirus, aimed at advancing the development and distribution of mRNA vaccines. This partnership not only enhances Arcturus's capacity to impact public health but also positions the company as a key player in the global race to combat infectious diseases through advanced vaccine technology. Complementing this international endeavor, Arcturus operates a joint venture in Japan, named ARCALIS, which focuses on the manufacturing of mRNA vaccines and therapeutics. These initiatives underscore the company's ambition to expand its reach and influence within the biopharmaceutical landscape.

Furthermore, Arcturus is actively working on treatments for specific genetic conditions, including ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF). The company is also engaged in partnered mRNA vaccine programs targeting SARS-CoV-2 and influenza, showcasing its versatility and commitment to addressing a broad spectrum of health challenges. With a robust intellectual property portfolio comprising over 400 patents and applications worldwide, Arcturus Therapeutics is well-positioned to lead the next wave of mRNA-based therapeutics, solidifying its role as a significant contributor to the future of medicine.

In anticipation of further developments, Joseph Payne, President & CEO of Arcturus, is set to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at 9:45 a.m. Pacific Time. This event provides a platform for the company to share its vision and advancements in the field of mRNA technologies with a broader audience.

For those seeking more information about Arcturus Therapeutics, the company encourages interested parties to visit its website at www.ArcturusRx.com and engage with the organization through social media channels like Twitter and LinkedIn.